Valeo Pharma 2Q results show same form as 1Q with guidance revealing record quarterly revenue

–News Direct–

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share guidance for the company’s second-quarter that reveal it is heading for the sixth straight quarter of record revenue.

The company said it expects 2Q revenue to exceed $13.5 million while its adjusted underlying (EBITDA) loss will decrease to below $2 million as the company heads to profitability.

Saviuk told Proactive the number continues to be driven by Asthma medications ENERZAIR and ATECTURA which saw quarterly revenues grow 270% over this time last year. In fact, the total number of prescribing physicians also grew and is now expected to exceeds 2,000.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/valeo-pharma-2q-results-show-same-form-as-1q-with-guidance-revealing-record-quarterly-revenue-745479485